Abstract
Bronchopulmonary dysplasia, or BPD, is the most common chronic lung disease in infants. Genetic predisposition and developmental vulnerability secondary to antenatal and postnatal infections, compounded with exposure to hyperoxia and invasive mechanical ventilation to an immature lung, result in persistent inflammation, culminating in the characteristic pulmonary phenotype of BPD of impaired alveolarization and dysregulated vascularization. In this article, we highlight specific areas in current management, and speculate on therapeutic strategies that are on the horizon, that we believe will make an impact in decreasing the incidence of BPD in your neonatal intensive care units.
Highlights
Bronchopulmonary dysplasia, or BPD, is the most common chronic lung disease in infants[1,2]
We have attempted to highlight specific areas in the current management of premature neonates that we believe will make an impact in decreasing the incidence of BPD in your neonatal intensive care units (NICUs)
In conclusion for how to decrease BPD today, consideration must be given to the pathogenesis and modifiable pathogenic factors that have supporting evidence
Summary
Bronchopulmonary dysplasia, or BPD, is the most common chronic lung disease in infants[1,2]. It was reported that, in a cohort of 1,433 very-low-birth-weight (
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
